CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.